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Objective: Stroke and traumatic brain injury (TBI) are among the leading causes of
disability. Even after engaging in rehabilitation, nearly half of patients with severe TBI
requiring hospitalization are left with major disability. Despite decades of investigation,
pharmacologic treatment of brain injury is still a field in its infancy. Recent clinical
trials have begun into the use of psychedelic therapeutics for treatment of brain injury.
This brief review aims to summarize the current state of the science’s relevance to
neurorehabilitation, and may act as a resource for those seeking to understand the
precedence for these ongoing clinical trials.
Methods: Narrative mini-review of studies published related to psychedelic therapeutics
and brain injury.
Results: Recent in vitro, in vivo, and case report studies suggest psychedelic
pharmacotherapies may influence the future of brain injury treatment through modulation
of neuroinflammation, hippocampal neurogenesis, neuroplasticity, and brain complexity.
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Conclusions: Historical data on the safety of some of these substances could serve
in effect as phase 0 and phase I studies. Further phase II trials will illuminate how these
drugs may treat brain injury, particularly TBI and reperfusion injury from stroke.
Keywords: psychedelics, neuroinflammation, neuroplasticity, stroke, brain injury, review

INTRODUCTION
Despite millennia of historical use around the world, research into medical uses of psychedelic
drugs has been stymied for years by stigma (1). “Classical” psychedelic drugs refer to the most
well studied and culturally significant psychedelics, including mescaline, lysergic acid diethylamide
(LSD), psilocybin, and dimethyltryptamine (DMT). Though having a wide range of molecular
structures and target receptors, psychedelics are unified by their ability to produce marked
alterations in sensory perception, consciousness, distortion of time, and perception of reality.
Evidence suggests that activation of 5-HT2A receptors (a class of excitatory receptors of serotonin
or 5-HT), is the common mechanism for the psychological experience of classical psychedelics,
though these compounds are known to act at other receptors (2).
Currently, however, psychedelics are experiencing a scientific renaissance due to advances in
research methodology and changes in the regulation of these substances. Trials of psilocybin for
disorders of consciousness, and DMT for stroke, are in discussion to begin in coming years (3, 4).
In vitro and in vivo studies suggest psychedelics may influence the future of brain injury treatment
in both the acute and chronic phases through a variety of mechanisms including modulation of
neuroinflammation, neuroplasticity, hippocampal neurogenesis, and increases in brain complexity.
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METHODS

rather than blunt reduction of the response, or “single-target”
approaches, is critical to improved outcomes.
Mizuma and Yenari (10) argue that immunomodulatory
therapies have previously not shown efficacy in clinical trials
because they largely took place before the use of revascularization
techniques. Because reperfusion injury is thought to be the
inciting event for much of the neuroinflammatory response, they
argue that combining revascularization with immunomodulation
may hold promise for stroke treatment. Indeed, Jickling et al.’s
(12) review of neutrophil modulation as treatment for stroke
notes the contrast seen in the efficacy of these treatments in
animal models is dependent on whether reperfusion is induced.
Classical psychedelics act principally on the 5hydroxytryptamine receptors (5-HTRs) to produce their
psychological effects, specifically the 5-HT2a receptor (5).
These same receptors are well-known to have the potential
to regulate inflammation within the central nervous system
and peripherally (15). In fact, the 5-HT2a receptor is the most
widely expressed serotonin receptor throughout the human body
(1). It is present on nearly all tissue and cell types, including
all major immune-related cell types (1). However, the highest
density of 5-HT2a receptors is found in the brain (1). Though
peripheral immunomodulation has been documented with
other psychedelics like lysergic acid diethylamide (LSD)
(16),
3,4-methylenedioxy-methamphetamine
(MDMA)
(17), and 2,5-dimethoxy-4-iodoamphetamine (DOI) (13),
N,N-Dimethyltryptamine (DMT) has been especially wellstudied with regards to its effects on neuroinflammation and
reperfusion injury.
DMT is a psychedelic which is endogenously produced
by the human brain, particularly the pineal gland, likely
in local concentrations comparable to other monoamine
neurotransmitters (18). Though it has been known for at least
40 years that DMT is an endogenously produced hallucinogen,
its physiologic function remains elusive. The lack of consensus
may be due in part to a paradigm in which the scientific
community has assumed DMT can only be, or primarily acts
as, a hallucinogen, which keeps research focus on its psychologic
effects at 5-HTRs, rather than its non-hallucinogenic effects (9).
Recent experiments have shown that an additional receptor, S1R,
is critical in the immunomodulating response of DMT.
S1R dysfunction is known to be involved in a wide range
of neurodegenerative diseases including Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, amyotrophic lateral
sclerosis (ALS), and TBI (19–21). S1R agonists produce
neuroprotective effects via regulation of intracellular calcium,
reducing expression of pro-apoptotic genes, and inhibiting antiapoptotic activity by the Bcl-2 gene (22). Specifically, DMT’s
action at S1Rs has been shown in murine models to modulate
inflammation by reducing IL-1b, IL-6, TNFa, and IL-8, while
increasing the secretion of the anti-inflammatory cytokine IL10, and by inhibiting activation of Th1 (T Helper cell type
1) and Th17 (T Helper cell type 17) subsets (20). In mice,
S1R is known to play an important role in the endoplasmic
reticulum stress response, including oxidative stress, probably
by up-regulating antioxidants, quinine oxidoreductase 1 and
superoxide dismutase (SOD) (23). Being present in reactive

We conducted a literature search of articles relevant to
psychedelic therapeutics for brain injury using PubMed. The
search terms are available in the Appendix. Bibliographies of
the main review papers were also used to detect other relevant
articles. Studies were selected with emphasis to their relevance to
psychedelics’ purported neuroregenerative and neuroprotective
potential, rather than their psychotherapeutic properties. A
narrative mini-review format was employed with the intention
of providing a brief overview for readers seeking to understand
the scientific basis for anticipated clinical trials.

NEUROINFLAMMATION
Within the brain, depression, addiction, Alzheimer’s, and
Parkinson’s all appear to be linked to neuroinflammatory
states (5–7). There are currently three main classes of
anti-inflammatory drugs: non-steroidal anti-inflammatory
drugs (NSAIDs), steroids such as prednisone, and biologics
which act like sponges to “soak up” inflammatory
cytokines (1). Psychedelics may represent a fourth class of
anti-inflammatory drug.
Neuroinflammation after stroke is responsible for both infarct
expansion as well as remodeling and repair (8, 9). Modulation
of this inflammation is currently a target for new therapies. The
inflammatory response to ischemic stroke is thought to derive
largely from reperfusion injury (10). In general, there are no
conventional medical therapies addressing reperfusion injury
after stroke, with the exception of edavarone in Japan, which is
only modestly effective (11).
After stroke, immune cells invade the injured tissue,
interacting with microglia and neurons (8). Modulating this
inflammatory response, particularly through tumor necrosis
factor (TNF), interleukin (IL)-1, IL-6, and IL-10, may be the next
frontier in stroke recovery (8, 12). However, it should be expected
that the cytokine response to brain injury has both beneficial
and harmful effects to the recovering patient. In contrast to
steroids, which cause generalized systemic immunosuppression,
psychedelics produce a unique pattern of cytokine expression
favoring anti-allergic conditions (13, 14). In other words,
psychedelics may target many of the pathologic immune
responses without exposing the body to the risks of total immune
suppression (e.g., serious infection) or potential side effects of
existing biologics (e.g., malignancy and cardiovascular disease).
Instead, careful regulation of the inflammatory response,
Abbreviations: 5HTR, 5-HT receptors; ALS, Amyotrophic lateral sclerosis; DMN,
Default-mode network; DMT, N,N-Dimethyltryptamine; DOI, 2,5-dimethoxy-4iodoamphetamine; DOC, Disorder of consciousness; EEG, Electroencephalogram;
fMRI, Functional magnetic resonance imaging; IL, Interleukin; LSD, Lysergic
acid diethyl amide; LZC, Lempel-Ziv complexity; MAOI, Monoamine
oxidase inhibitor; MCAO, Middle cerebral artery occlusion; MDMA, 3,4methylenedioxymethamphetamine; MVF, Mirror visual feedback therapy; NFAT,
Nuclear factor of activated T-cells; REM, Rapid eye movement sleep; S1R, Sigma-1
receptor; TBI, Traumatic brain injury; THC, Tetrahydrocannabinol; TLR, Toll-like
receptor; TNF, Tumor necrosis factor; SOD, Superoxide dismutase.
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seen when high dose psilocybin was administered onceper-week, avoiding the issue of rapid tolerance buildup
via 5HTR downregulation (33). Targeting hippocampal
neurogenesis for treatment of brain injury and other
psychiatric and neurologic disorders is an emerging area of
research (36).

astrocytes, microglia, and neurons, it has also been shown
to regulate neuritic outgrowth, myelination, synaptogenesis,
and neuro-regeneration (22, 24). It should be noted that
S1R is now known to have multiple endogenous agonists,
such as progesterone (25). However, with no clear alternative
explanation, it may be reasonable to hypothesize that DMT has
some, or all, of these neuroprotective and anti-inflammatory
physiologic functions as well. The only clinical trial of a
selective S1R agonist for treatment of stroke showed statistically
significant functional recovery in post-hoc analysis of moderatelyto-severely affected patients (26).
DMT has been shown to reduce ischemic brain injury
after middle cerebral artery occlusion (MCAO) through S1R
dependent activity in murine models (27). Nardai et al. (27)
documented a significant reduction of the infarct core volume
in rats at 24 h post MCAO with administration of DMT, as well
as enhanced functional regeneration of the affected limb at 30
days post MCAO (27). These results are consistent with other
in vitro studies showing cytoprotective effects of DMT against
reperfusion injury (28). Furthermore, similar effects have been
documented in human-specific models including human cerebral
organoids. Dakic et al. (22) were the first to document that a
closely related congener of DMT, 5-MeO-DMT, found in high
concentrations of the toxin of Incilius alvarius (Colorado River
Toad), favorably altered the cerebral proteome with regard to
factors involved with plasticity and neuroprotection including
long-term potentiation, apoptosis, morphogenesis/maturation
of dendritic spines, and T-lymphocyte differentiation, while
inhibiting factors involved in neurodegeneration and cell death.
The authors note that other dimethyltryptamines may have
similar effects, but their results show that the mechanisms
may be different and that each deserves careful study. Previous
studies in monolayer neuronal cultures did not show the same
effects, suggesting a more complex circuitry is required for these
effects (22).

NEUROPLASTICITY
Novel interventional approaches hold promise to improve
functional outcomes after brain injury by inducing neural
plasticity. However, like targeting inflammation and
hippocampal neurogenesis, targeting neuroplasticity is a
double-edged sword. Ischemia induced plasticity may be
responsible for recovery of function, but also drive complications
such as epilepsy and memory disturbance. A full discussion on
ischemia induced plasticity is available elsewhere (37).
Functional recovery due to post-stroke plasticity is currently
most effectively recruited through intensive physical therapy
(37). However, both non-invasive techniques for inducing
neuroplasticity such as transcranial magnetic stimulation and
direct current stimulation, as well as invasive techniques such
as deep brain stimulation, show promising results for stroke
recovery (37).
The search for pharmacologic agents which stimulate
neuroplasticity after brain injury, including amphetamines,
dopaminergic, serotonergic, noradrenergic, and cholinergic
agents, has thus far been inconclusive. To our knowledge,
the effect of psychedelics on neuroplasticity has not been
tested in brains subjected to injury such as stroke. However,
recent reports demonstrate that psychedelics promote both
structural and functional neuroplasticity in non-injured brains.
The persistent symptom improvement in psychiatric disorders
with administration of psychedelics has been proposed to be
driven by this neuroplastic adaptation (2). Ly et al. (38) found
that some psychedelics were more efficacious (e.g., MDMA) or
more potent (e.g., LSD) than ketamine in promoting plasticity.
These results were demonstrated in vivo in both non-human
vertebrates and invertebrates, suggesting that these mechanisms
are evolutionarily conserved.
One hypothesized mechanism for psychedelics’ beneficial
effect on neuroplasticity in brain injury is via Brain-derived
neurotrophic factor (BDNF), which is well-known to be
implicated in both neuritogenesis and spinogenesis (39). In Ly
et al.’s (38) experiments, they found that many psychedelics
rivaled administration of pure BDNF in their ability to induce
plasticity. At least one randomized control trial has demonstrated
increases in serum BDNF in volunteers with administration
of a DMT containing tisane, ayahuasca, which persisted for
48 h (40). Importantly, ayahuasca, a traditional South American
ceremonial brew, contains not only DMT, but also β-carbolines
which act as reversible monoamine oxidase inhibitors (MAOIs)
potentiating and prolonging the effects of DMT (40). However,
it should be noted that many other non-psychedelic drugs have
failed to alter the course of brain injury through induction
of BDNF.

HIPPOCAMPAL NEUROGENESIS
TBI and stroke alter hippocampal neurogenesis in murine models
(29, 30). Though hippocampal neurogenesis is recognized as an
important component of cognitive recovery from TBI and stroke,
there is not a direct correlation between increased neurogenesis
and recovery. Complicating factors include the nature of the
injury, the timing of intervention, how the cells integrate into
the hippocampal circuits, and whether the target of intervention
is either increased neuronal proliferation or increased survival.
While hippocampal neurogenesis after TBI is implicated in
improved cognition, relief from depressed mood, and encoding
of episodic memory, it is also associated with pro-epileptogenic
changes and spatial memory impairment (29, 31, 32).
Though many factors are implicated in hippocampal
neurogenesis, one of the most important is 5HTR stimulation
(33, 34). Acute administration of psilocybin to mice alters
hippocampal neurogenesis in a non-linear fashion (35). Low
doses lead to increased neurogenesis while higher doses
inhibit it. However, increased neurogenesis has also been
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agonism is associated with increased neuroplasticity, while
antagonism is associated with reduced cognitive flexibility
and increased slow-wave sleep and sedation (56, 57). These
receptors are most densely expressed in the cortical areas
belonging to the default-mode network (DMN) (52). The DMN
is known to be implicated in conscious processing as well as the
subjective experience of psychedelic states (52). Strength of DMN
connectivity is significantly decreased in stroke patients with
DOCs, and is highly correlated with Glasgow Coma Scale scores
(58). Secondarily, 5HTRs have been shown to play an important
role in the control of thalamo-frontal connectivity, known to be
important for consciousness (59, 60).

However, there is also evidence to suggest that S1R is an
important part of the plasticity response to stroke. For example,
Ruscher et al. (41) found that delivery of a synthetic S1R agonist
enhanced plasticity-mediated recovery of lost sensorimotor
function in rats, even when initiation of therapy was started up
to 2 days after MCAO, possibly expanding the currently very
narrow therapeutic window for acute stroke.
Mirror visual-feedback (MVF) has been shown to enhance
key features of neuroplasticity including cross-modal cortical
reorganization and learning (42). In patients <12 months post
stroke, MVF therapy enhances functional recovery of lower
limbs and hands (43, 44). Psilocybin combined with mirror
visual-feedback has been shown in a case report to have a
dose-dependent reduction in phantom limb associated pain,
hypothesized to be due to facilitating MVF’s ability to “unlearn”
paralysis via 5HTR-dependent changes in neuroplasticity (42).
Clinical trials for use of psilocybin in phantom limb pain are
currently underway (45).

CONCLUSIONS
Psychedelics may play a future role in treatment of brain
injury through a variety of mechanisms. Though these are
a novel class of drugs deserving close study, more data are
necessary to prove their efficacy for treatment of brain injury,
as historically many compounds have seemed promising in
vitro, including likely hundreds of compounds thought to
facilitate neuroplasticity and neuroprotection, but have not
borne out in clinical trials (61, 62). There is already mixed
evidence to suggest the use of non-classical psychedelics
ketamine (63, 64), as well as tetrahydrocannabinol (THC)
(65, 66) and cannabidiol (67, 68), as neuroprotectants after
TBI and stroke. Presence of THC on urine drug screen is
associated with decreased mortality in adult patients sustaining
TBI (65). However, randomized control trials of a nonpsychoactive cannabinoid analog, dexanabinol, administered
once after TBI has failed to show benefit over placebo in
increasing Glasgow Coma Scores at 6 months post-injury
(69). One explanation for this discrepancy may be the
lack of “entourage” effect whereby various cannabinoids and
cannabis phytochemicals are clinically more efficacious when
working synergistically compared to administration of a single
cannabinoid in isolation (70), though the existence of such
an effect with cannabis is contentious with mixed evidence
for its existence (71). Of note, an “entourage” effect has been
demonstrated with psychedelic mushrooms in which whole
mushroom extracts are on the order of 10 times more potent
than purified psilocin administered alone in neurobehavioral rat
models (72).
Another possible explanation is that the subjective
hallucinogenic effects are necessary for some, or all, of
psychedelics’ therapeutic effects. This remains a fundamental
research question and strong evidence exists on both sides
of the debate (73). Few human trials on the therapeutic
effects of psychedelics at sub-behavioral “micro-” doses have
been completed, but results from animal and cell studies
for their use as anti-inflammatories are promising (5). In
contrast, studies on the psychological effects of micro-dosing
psychedelics seem to be explained by placebo effect (74, 75).
Extrapolating from animal studies, the doses required at least
for the anti-inflammatory effects of psychedelics are predicted
to be magnitudes less than threshold for hallucinations (13).

INCREASE IN BRAIN COMPLEXITY
Disorders of consciousness (DOC) can arise from a variety
of brain injuries including trauma, hypoglycemia, anoxia, and
stroke. Between 4 and 38% of stroke patients will experience
a DOC (46). Though many therapies have been proposed for
patients with DOC, including pharmacologic (e.g., amantadine,
D-amphetamine, levodopa, modafinil, and zolpidem), invasive
and non-invasive stimulation (e.g., transcranial direct current
stimulation), benefits for functional recovery are usually modest
and current evidence supporting their use is inconsistent (47–50).
Other stimulants acting on dopamine including apomorphine
may hold promise (51).
Scott and Carhart-Harris have proposed an experimental
protocol for testing the capacity of psilocybin to increase
conscious awareness in patients with DOC (52). They
hypothesize psychedelics increase brain activity complexity
and conscious content, in contrast to current stimulant drugs
that increase arousal. However, to our knowledge there are no
studies of brain complexity measures in DOC patients given
stimulants. Their hypothesis relies on findings that psilocybin
increases brain complexity, and that these particular measures
of complexity, namely perturbational complexity index (53) and
the closely related Lempel-Ziv complexity (LZC), reliably predict
conscious level. They argue that psychedelic-related elevations
in LZC reflect an increased richness of conscious experience,
and that targeting increases in conscious content, rather than
arousal, as with stimulants, may be key to increasing conscious
awareness in DOC patients.
In human subjects, increases in LZC have been observed in
excess of those seen in normal wakefulness with administration
of psilocybin, LSD, and ketamine at psychedelic doses (54). This
increase in complexity has also been demonstrated via other
measures including electroencephalogram (EEG) and functional
magnetic resonance imaging (fMRI) (55).
Psychedelics are thought to increase brain complexity
primarily through 5HTRs (53). As previously discussed, 5HTR
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Furthermore, recent studies treating rat models of asthma
with 2,5-dimethoxyphenethylamine (2C-H) which is a nonhallucinogenic 5-HT2a agonist structurally related to MDMA,
suggest that psychedelics’ behavioral and anti-inflammatory
effects may have separate, but related, underlying mechanisms
(76). A non-hallucinogenic analog of ibogaine has been shown
to induce structural neuroplasticity, as well as reduce depression,
alcohol-, and heroin-seeking behavior in rodents, similarly
to its hallucinogenic variant (77). In contrast, Brouwer and
Carhart-Harris have introduced a construct known as the
“pivotal mental state” to explain the evolutionary function
that 5-HT2a receptor agonism has in inducing neurologic
hyper-plasticity and psychological adaptation when the body
is exposed to subjective acute stress (e.g., hallucinations,
intense spiritual experience, psychosis, trauma) (78). They
hypothesize that “psychedelics hijack a system that has
evolved to mediate rapid and deep learning” to provide
a psychological “fresh start” or “rebirth.” It is likely that
some, but not all, of the psychological therapeutic benefits of
psychedelics is dependent on the subjective experience (73),
but whether the same can be said for their use in brain injury
is unclear.
Classical psychedelics have millennia of historical use, do not
have significant risk of dependence, and are safe to use under
close medical supervision (79, 80). Though there should be
caution in over-interpreting the relevance of the aforementioned
animal studies’ relevance to human pathological states, this
historical data should serve in effect as phase 0 and phase I studies
(9). However, presumably much of this historical data is based
on intermittent, infrequent dosing, so trial safety data may need
to be repeated with continuous, regular doses. Further phase II

trials will illuminate how these drugs may treat brain injury,
particularly TBI and reperfusion injury from stroke.
Further study and design of non-psychoactive analogs
may answer fundamental questions regarding the interplay of
hallucinations with other properties of psychedelic therapy,
as well as facilitate more practical use in acute hospital
settings. The subjective hallucinogenic effects of psychedelics,
with clinical psychological support, may also prove valuable in
fostering recovery from brain injury from a trauma recovery
rehabilitation psychology standpoint due to their anti-PTSD
and anti-depression effects that are now well-documented (81,
82). Depression and PTSD significantly hinder recovery from
stroke and TBI (83, 84). Psychedelics’ use in this area may be
more immediately clinically relevant in this area than in the
neuroprotection and neuro-regeneration, where comparatively
less is known. Further research is needed to determine the
optimal timing after injury and route of administration for
neuroprotective effects. All the compounds discussed in this
paper have reasonable oral absorption. Route of administration
would impact the degree and timeliness of the pharmacological
effects yet there are not enough studies specifically on this aspect
to make recommendations. The emerging use of intranasal route
of administration may afford rapid induction into the central
nervous system and could be a promising future option (85).
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73. Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow
phenomenon: when and how do therapeutic effects of hallucinogens
depend on psychedelic experiences? J Psychopharmacol. (2015) 29:241–
53. doi: 10.1177/0269881114568040

Frontiers in Neurology | www.frontiersin.org

Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Khan, Carter, Aggarwal and Holland. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.

7

July 2021 | Volume 12 | Article 685085

Khan et al.

Psychedelics for Brain Injury

APPENDIX
((psychedelics) OR (psychedelic) or (psilocybin) or (psilocin)
or (dimethyltryptamine) or (N,N-Dimethyltryptamine)
or (N,N-DMT) or (5-MeO-DMT) or (MDMA) or (3,4Methylenedioxymethamphetamine) or (LSD) or (lysergic acid
diethylamide)) and ((disorders of consciousness) or (DOC) or
(inflammation) or (stroke) or (brain injury) or (reperfusion) or
(TBI) or (trauma) or (neuroplasticity)).
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